Sputum Gram Stain Helps Predict Etiology of Bacteremic CAP

A Prospective Study of the Diagnostic Utility of Sputum Gram Stain in Pneumonia.
For patients with bacteremic CAP who were producing sputum, sputum Gram stain had high sensitivity, specificity, positive predictive value, and negative predictive value for identification of the etiologic agent.
Background:
The utility of sputum Gram stain in determining the etiology of bacterial pneumonia is controversial.
Objective: To determine the accuracy and utility of sputum Gram stain in diagnosing the etiology of bacteremic community-acquired pneumonia (CAP).
Participants/Methods: A prospective study of all patients with a diagnosis of CAP at 2 hospitals in Greece was undertaken between January 2002 and June 2008. To be included in the study, patients had to meet the CAP clinical criteria, have had no antimicrobial therapy in the past 2 weeks, lack evidence for infection outside of the pulmonary system, and have the same organism isolated from blood and sputum cultures. Sputum was collected upon admission, and Gram stain was performed and read by 2 experts who were blinded to the blood and sputum culture results. Gram stain was interpreted as follows: Gram-positive diplococci indicated Pneumococcal pneumonia, Gram-positive cocci in clusters indicated staphylococcal pneumonia, and Gramnegative coccobacilli suggested Haemophilus influenzae pneumonia.
Results:
Of the 1390 patients with CAP, 178 were producing quality sputum and had the same microorganism isolated from sputum and blood culture. Of these selected patients, 52% had pneumococcal pneumonia, 14% had staphylococcal pneumonia, 16% had H. influenzae pneumonia, and 18% had Gram-negative bacilli pneumonia. The Gram stain sensitivity was 0.82 for pneumococcal pneumonia, 0.76 for staphylococcal pneumonia, 0.79 for H. influenzae pneumonia, and 0.78 for Gram-negative bacilli pneumonia. The Gram stain specificity was 0.93 for pneumococcal pneumonia, 0.96 for staphylococcal pneumonia, 0.96 for H. influenzae pneumonia, and 0.95 for Gram-negative bacilli pneumonia. The positive predictive value was highest for pneumococcal pneumonia, whereas the negative predictive value was highest for nonpneumococcal pneumonia etiologies.
Conclusions:
Reviewer's Comments: The use of Gram stain to assist with the diagnosis and management of CAP has its adherents and detractors. This study, which provides data in support of using sputum Gram stains in patients with CAP, has several strengths. It was done in a prospective fashion with active efforts to obtain high-quality sputum; the Gram stain was done by 2 persons blinded to additional results, and it included data from 4 major distinct causes of pneumonia rather than focusing of pneumococcal disease alone. Its major disadvantage is that it studied a highly selected portion (approximately 15%) of patients with CAP meaning that these data cannot be generalized to all CAP patients. Nevertheless, these data demonstrate that, when bacteremic patients with CAP are producing good quality sputum, Gram stain of the sputum could assist with the early identification of the etiologic agent.
New Therapy for Inhalation Anthrax?
Raxibacumab for the Treatment of Inhalational Anthrax. A monoclonal antibody against anthrax protective antigen ameliorates experimental inhalational anthrax in rabbits and monkeys.
Background: Inhalation anthrax causes high mortality primarily as a result of injury due to toxins produced by Bacillus anthracis. Antitoxin-specific pharmaceuticals may improve the outcome of disease due to B. anthracis.
Objective:
To determine the effectiveness of raxibacumab, a human IgG1lambda monoclonal antibody directed against B. anthracis protective antigen, in animal models of B. anthracis disease as well as the safety of raxibacumab in healthy humans.
Methods:
The efficacy of raxibacumab as a prophylactic and therapeutic agent was determined in rabbits and monkeys challenged with 100 times (prophylactic evaluation) and 200 times (therapeutic evaluation) the lethal dose of aerosolized B. anthracis. In the therapeutic intervention, animals were monitored for a significant increase in temperature or the presence of protective antigen in their serum; if detected, the animals then received either placebo or raxibacumab at 20 mg/kg or 40 mg/kg. The primary end point was survival at day 14 (rabbits) or day 28 (monkeys). Safety studies were done by infusing 40 mg/kg of raxibacumab in healthy humans.
Results:
The administration of raxibacumab as prophylaxis increased survival in both rabbits and monkeys, from 70% to 90% among treated animals depending on dose versus 0% in animals that received placebo. The administration of raxibacumab therapeutically increased rabbit survival from 0% in the placebo group to 28% in the 20-mg/kg group and 44% in the 40-mg/kg group. A similar increase in survival was observed in monkeys treated in a therapeutic fashion with survival rates of 50% in the 20-mg/kg group and 64% in the 40-mg/kg group compared to 0% in the placebo group. The administration of raxibacumab at 40 mg/kg to healthy humans did not result in a significant difference in adverse events compared to persons who received a placebo infusion.
Conclusions:
The administration of a monoclonal antibody directed at B. anthracis protective antigen significantly increased survival in rabbits and monkeys challenged with B. anthracis in a preventive and therapeutic fashion.
Reviewer's Comments:
The events of 2001 clearly demonstrate that new treatments for inhalation anthrax are needed as mortality remains high even after treatment with antimicrobials. Given that most, if not all, of the clinical manifestations of anthrax are the result of toxin-mediated disease, anthrax may be particularly amenable to a targeted antibody strategy as outlined in this manuscript. I was particularly impressed by the ability of raxibacumab to cure established anthrax disease, as we often see data regarding the efficacy of preventive measures, which have little clinical applicability. The fact that human challenge with anthrax is unethical means these data may result in the use of raxibacumab along with antibiotics in future cases of inhalation anthrax.
Additional Keywords: None
Microbiologic Events Leading Up to rUTI
Prospective Cohort Study of Microbial and Inflammatory Events Immediately Preceding Escherichia coli Recurrent Urinary
Tract Infection in Women. Periurethral colonization of E. coli peaks 2 to 3 days before rUTI.
Background: Recurrent urinary tract infections (rUTI) due to Escherichia coli cause significant morbidity and health-care resource utilization. The pathophysiology of E. coli rUTI remains poorly understood.
Objective: To characterize the temporal sequence of bacterial presence and host inflammatory events immediately preceding E. coli rUTI.
Participants/Methods: Women (age range, 18 to 49 years) diagnosed with acute cystitis and who had a history of UTI within the past year, self-collected daily periurethral and urine samples. Patients were taught to perform daily leukocyte esterase testing of the urine and to record urinary symptoms and episodes of sexual intercourse. Cytokines were measured on urine specimens. E. coli rUTI was defined as the presentation of the subject to the clinic for symptoms of acute cystitis along with an E. coli concentration in the urine of ≥1 x 102 CFU/mL.
Results: 104 women were enrolled in the cohort, with 85% of the enrollment UTIs being caused by E. coli. Among the 104 women, 36 subjects had a total of 49 rUTIs with 38 episodes being due to E. coli; 67% of the E. coli rUTIs were caused by the same E. coli strain as the initial infection as determined by pulsed-field gel electrophoresis (PFGE). The periurethral prevalence of the rUTI E. coli strain increased from 46% 14 days before the rUTI to 90% 1 day before the rUTI. The presence of bacteruria was 7% 14 days before the rUTI and increased to 70% 1 day before rUTI. The presence of detectable urine leukocyte esterase was 31% 14 days before rUTI and increased significantly to 64% the day before the rUTI. Eleven women had the combination of E. coli bacteruria along with urinary symptoms in the 2 to 3 days prior to presenting to the clinic (so-called preclinical UTI). Strains of E. coli from patients with preclinical UTI were less likely to have known E. coli virulence determinants such as P fimbriae. The peak prevalence of periurethral carriage of E. coli and sexual intercourse occurred 3 days before rUTI. Urinary cytokines (IL-6 and IL-8) rose significantly on the day of rUTI.
Conclusions:
The prevalence of periurethral E. coli, bacteruria, pyuria, and sexual intercourse increased dramatically in the days immediately preceded an E. coli rUTI.
Reviewer's Comments: Understanding the clinical and microbiological events leading to recurrent infections, such as rUTI, is critically important to designing rational prevention strategies. This well-done, prospective, cohort study clearly shows that the prevalence of E. coli and host inflammation are dramatically increased in the days immediately preceding a recurrent E. coli UTI. Sexual intercourse in the setting of periurethral E. coli colonization appears to be the most important trigger for rUTI among young women. This constellation of findings suggests that a pre-emptive antimicrobial strategy could be designed in patients at high risk of rUTI. Treatment of asymptomatic bacteriuria in diabetic women does not reduce long-term infections with these nondisease causing strains.
Background: Urinary tract infections are seen frequently in women with diabetes. In addition, asymptomatic bacteriuria (ASB) also occurs more frequently in diabetic women. Escherichia coli is the most common infecting organism. It is unclear if the persistent E. coli in diabetic women with ASB is from the same strain and whether therapy eradicates the organism.
Objective: To determine whether the persistent E. coli ASB in diabetic patients is caused by the same E. coli strain and what the effect of treatment is in patients who genetically carry similar versus different E. coli strains.
Participants/Methods: 70 women who had at least 2 consecutive urine samples over a 2-week period were randomized to receive a trial of antimicrobial agents or no antimicrobial treatment unless they developed a symptomatic infection. Women were followed for 36 months. E. coli isolates were typed as well as analyzed for particular virulence factors.
Results: There were 517 total E. coli isolates. Seventeen percent of the women had bladder neuropathy and 16% had undergone previous genitourinary surgery. The women had ASB during 36% of the follow-up time, with a mean duration of 2.6 months. They carried a single unique strain for an average of 2.8 months. Approximately 25% of women who had follow-up for >6 months remained continuously colonized with a single strain for at least 6 months. Of the 34 women, 22 in the no-treatment group had a symptomatic UTI at least once during the follow-up. Sixty-four percent of the women who received treatment for ASB had recurrent E. coli bacteriuria with a new strain.
Reviewer's Comments:
This study illustrates a few interesting points about diabetic women with ASB. First, untreated diabetic women can carry the same strain of E. coli for a long period of time. These strains do not possess many of the virulence factors that disease-causing strains have. Second, if you treat these women with antibiotics, a new strain will eventually take the old one's place. Therefore, the repeated use of antibiotics does not reduce the amount of ASB over the long term in diabetic women, and treatment should be focused on those who present with symptomatic disease.
Additional Keywords: None The onset of symptoms occurs more quickly when Gram-negative pathogens cause PJIs compared to Gram-positive pathogens.
Gram-Negative Pathogens Are Frequent Cause of PJIs
Gram-Negative Prosthetic Joint Infections: Risk Factors and Outcome of Treatment.
Background: Prosthetic joint infections (PJIs) occur in approximately 1% to 2% of all patients at most medical centers. Most PJIs are caused by Gram-positive pathogens, but Gram-negative pathogens are also found in a significant number of cases, and they can be difficult to treat. Risk factors and outcomes in patients with PJIs caused by Gram-negative pathogens are not as well studied.
Objective: According to the authors, their objective was, "...to evaluate the demographic characteristics and outcomes of patients treated for Gram-negative (GN) PJI and to identify prognostic factors that would lead to treatment failure."
Design: Retrospective case cohort study.
Participants/Methods:
Patients diagnosed with PJI in the hip or knee from January 2000 through December 2006 were included in the study. A GN PJI was defined as the presence of at least 1 GN pathogen at the infected site regardless of the total number of different strains present.
Results: There were 53 first-time episodes of GN PJI in 50 patients, which accounted for 15% of all the firsttime episodes of culture-positive PJI. The most commonly isolated organism was Pseudomonas aeruginosa, with 21 episodes, followed by Escherichia coli with 10 episodes. Only 27% of patients with debridement had a 2-year survival free of treatment failure. This compared to 87% who had a 2-stage exchange arthroplasty and 69% in those who had resection arthroplasty. Out of 27 patients treated with debridement and retention, treatment failure was seen in 74%. The only risk factor that was found for those who failed treatment was a longer duration of symptoms before the treatment (11 days vs 5 days).
Conclusions:
Gram-negative pathogens cause a significant number of PJIs. Debridement and retention of the prosthesis is successful only in a small percentage of patients and should be used only in those who have had symptoms of short duration.
Reviewer's Comments: This study was a nice reminder that Gram-negative pathogens are not an infrequent cause of PJIs. The major points that the clinician should be aware of are the fact that debridement with retention of the prothesis (even with prolonged antibiotics) did not lead to treatment success in the majority of patients. For the approximately 25% of patients who did respond to this approach, they had surgery within days of the patient's onset of symptoms. The authors propose using this treatment approach only in these patients. The increased virulence and antibiotic resistance seen in Gram-negative pathogens makes treating these patients challenging.
Is Dexamethasone Effective in C. gattii CNS Infection?
Dexamethasone in Cryptococcus gattii Central Nervous System Infection. Corticosteroids may be beneficial in patients with Cryptococcus gattii CNS infection who have persistent mental status abnormalities along with focal lesions on brain scans in spite of having received adequate antifungal therapy.
Objective: To describe the results of dexamethasone treatment of 4 patients with Cryptococcus gattii central nervous system (CNS) infection who had persistent mental status changes in spite of adequate antifungal therapy and control of intracranial pressure.
Participants: 4 patients with complicated CNS disease from a group of 17 patients with C. gattii infection.
Methods:
The charts of all patients with C. gattii infection who were treated with systemic corticosteroids at 3 hospitals in the greater Vancouver area were retrospectively reviewed. Four patients were identified who had CNS involvement, but these patients also had persistent or worsening mental status abnormalities after receiving adequate antifungal therapy and mechanical control of increased intracranial pressure.
Results: Between January 1, 2004, and December 31, 2007, 17 patients were identified with culture-proven C. gattii infection. Eleven of these patients had CNS infection, and 6 were administered corticosteroids; 2 received these steroids before a definitive diagnosis of C. gattii infection was made. Four patients were identified who had been treated with amphotericin B for periods of time (range, 26 to 56 days), and had been documented to have achieved negative cerebrospinal fluid cultures. Despite adequate antifungal therapy and control of increased intracranial pressure by lumbar drains or ventriculoperitoneal shunting in 2 patients, these 4 patients had persistent mental status changes. Furthermore, 3 of the 4 patients demonstrated new or worsening CNS lesions on brain imaging. Therapy with dexamethasone resulted in improvement of mental status changes, in most cases within just 1 to 2 days. These clinical changes were accompanied by radiographic improvement as well. No significant adverse events were noted.
Conclusions:
In patients treated for C. gattii CNS infection who have persistent mental status changes accompanied by radiographic abnormalities, dexamethasone may provide effective adjunctive therapy.
Reviewer's Comments: C. gattii has a greater propensity to affect immunocompetent patients than does C. neoformans. Because most affected individuals have normal immunological function, antifungal therapy may result in a paradoxical clinical exacerbation akin to the immune reconstitution inflammatory syndrome seen in AIDS patients with opportunistic infections who are started on HAART. This paper provides anecdotal evidence that corticosteroid therapy may be beneficial in the subgroup of patients who appear to have that paradoxical exacerbation. The authors suggest that further studies should be performed to test this particular therapeutic strategy. Therapeutic modalities were quite variable; however, 10 patients were initially treated with caspofungin alone (7) or in combination with other drugs (3). Five patients had valve replacement, all of whom were discharged without signs of infective endocarditis. The 6 patients who did not have surgery all died. Three of 4 patients treated with medical therapy alone were cured, but these patients all had catheter-or pacemaker-related infections and received prolonged therapy.
Candida endocarditis usually affects individuals who have intravascular prosthetic devices. The diagnosis is frequently delayed, resulting in substantial morbidity and mortality. Successful therapy usually requires the use of cidal antifungal agents, most commonly caspofungin, along with surgery.
Reviewer's Comments: The in-hospital mortality for Candida endocarditis approaches 50%; consequently, newer approaches to therapy need to be sought. In this study, most patients received caspofungin, a much safer and easier drug to administer than amphotericin B. In vitro studies support the use of echinocandins instead of amphotericin B.
